$cPLA_2$, wherein said inhibitor interacts with one or more atoms of said one or more amino acids in the $cPLA_2$ active site, and wherein said one or more atoms is selected from the group consisting of:

CB and Oγ atoms of Ser228;

Oδ1and Oδ2 atoms of Asp549 and Asp575;

CB, CG, CD, NE, CZ, NH1 and NH2 atoms of Arg200, Arg413 and Arg579;

Backbone carbonyl oxygen of Trp393;

Nδ2 and Oδ1 atoms of Asn555;

Atoms CD1, CE1, CG, CZ, CE2, and CD2 of Phe397, Phe681, Phe683 and Phe199;

CG, CD1, NE1, CE2, CZ2, CH2, CZ3, CE3 and CD2 of Trp232 and Trp393;

CB and Oγ atoms of Ser577;

Atom s CB and Sγ of Cys331;

Atoms OE1 and OE2 of Glu589;

Atoms CB, CG, CD, CE and NZ of Lys588;

Oγ1 atom of Thr680;

OE1 and OE2 atoms of Glu418 and Glu422;

Atoms CB, CG, SD and CE of Met417;

Atoms CB, CG, CD1 and CD2 of Leu400 and Leu421;

Atoms CB, CG1, CG2, or CD1 of Ile424;

Backbone NH and carbonyl oxygen atoms of Ala578; and

Atoms CB, CG, ND1, CE1, NE2, and CD2 of His639.

D2

Please add new claims 30 and 31 as follows:

---

30. **(New)** The method of claim 22, wherein said activity of $cPLA_2$ is lipid binding.

D3

31. **(New)** The method of claim 22, wherein said activity of $cPLA_2$ is membrane binding.